Astute Medical has entered into a strategic collaboration with Ortho-Clinical Diagnostics (OCD) that will expand access to a new test that evaluates critically ill patients for risk of acute kidney injury (AKI), a prevalent and deadly condition.
According to a study recently published in the Journal of the American Society of Nephrology, AKI could be more deadly than heart attack.
As part of the multi-year deal, Astute Medical has designated OCD as the exclusive sales agent for Astute’s NephroCheck Test and Astute140 Meter in certain countries of the EU and in the US if approved.
Currently, the NephroCheck Test and the Astute140 Meter are not available for sale in the US and the company is pursuing regulatory clearance to market both in the country.
In addition, OCD also secured a semi-exclusive worldwide licence to develop and commercialise a version of the NephroCheck Test for use on its VITROS line of automated, high-volume testing platforms.
According to the company, the test developed for the OCD platform will require separate regulatory clearances before it can be sold.
Astute Medical chief executive officer Chris Hibberd said: "We believe there is a tremendous unmet need for improved tools in AKI and are delighted to be working with OCD to address this important medical condition."
OCD chairman and chief executive officer Martin Madaus said: "Astute’s innovative approach and product is a perfect fit with the commercial strength of OCD and our desire to advance important new diagnostic tests."
Both the firms have not disclosed further financial details of the agreement, under which OCD has made a $15m equity investment in Astute Medical.
Astute’s current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.
Image: Currently, Astute’s NephroCheck Test and the Astute140 Meter are not available for sale in the US. Photo: courtesy of Astute Medical.